← Back to Clinical Trials
Recruiting NCT05776316

NCT05776316 Harm Reduction Services

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05776316
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Drug Use
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-11-25
Primary Completion 2026-09-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Integrated Harm Reduction Intervention (IHRI)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-11-25 with a primary completion date of 2026-09-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).

Eligibility Criteria

Inclusion Criteria: * at least 18 years of age * self-identified as misusing opioids +/- other substances (stimulants) in the past 30 days, confirmed by interview using DSM-5 criteria * English or Spanish speaking * able to provide informed consent. Exclusion Criteria: * inability to provide informed consent or participate in the study procedures as proposed in the consent * active suicidal or homicidal ideation or an unstable psychotic disorder (schizophrenia, schizoaffective disorder) or mood disorder (bipolar disorder, severe major depressive disorder) * an unwillingness to be randomized. * are prisoners

Contact & Investigator

Central Contact

Ayana Jordan, MD, PhD

✉ Ayana.Jordan@nyulangone.org

📞 (203) 787-8032

Principal Investigator

Ayana Jordan, MD, PhD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT05776316 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Drug Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05776316 currently recruiting?

Yes, NCT05776316 is actively recruiting participants. Contact the research team at Ayana.Jordan@nyulangone.org for enrollment information.

Where is the NCT05776316 trial being conducted?

This trial is being conducted at New Haven, United States, New York, United States, Orangeburg, United States.

Who is sponsoring the NCT05776316 clinical trial?

NCT05776316 is sponsored by NYU Langone Health. The principal investigator is Ayana Jordan, MD, PhD at NYU Langone Health. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology